替拉珠单抗对银屑病表观遗传衰老偏移的影响:52周开放标签研究
这项52周开放标签试验纳入20例中重度银屑病成人患者,接受替拉珠单抗-asmn 100 mg注射至第28周,并设10例无银屑病年龄匹配对照。全血白细胞DNA甲基化分析显示,银屑病患者死亡预测表观遗传时钟加速,替拉珠单抗治疗可部分逆转PCGrimAge。
要点
- 银屑病患者死亡预测表观遗传时钟加速。
- 替拉珠单抗可部分逆转PCGrimAge偏移。
- 研究为小样本试点研究,需谨慎解读。
核心结论
- 银屑病患者死亡预测表观遗传时钟加速,替拉珠单抗治疗28周可部分逆转这些时钟。
研究设计与样本
- 开放标签52周临床试验,20例中重度银屑病成人接受替拉珠单抗-asmn 100 mg注射至第28周,10例年龄匹配无银屑病对照。
- 全血白细胞DNA甲基化谱(MethylationEPICv2.0)计算表观遗传衰老时钟,表观遗传年龄偏移以相对实际年龄的残差表示。
主要发现
- 银屑病患者死亡预测时钟表观遗传年龄偏移增加:PCGrimAge(P = .008)、CpG PTPCGrimAge3(P = .019)、CpGPTGrimAge3(P = .019)、GrimAge2(P = .049)。
- PCGrimAge在使用替拉珠单抗-asmn后第28周逆转0.3年(P = .005),第52周逆转0.5年(P = .04)。
- 银屑病患者衰老速度增加:DunedinPACE(P = .049)。
临床怎么用
- 白细胞DNA甲基化时钟可作为评估银屑病系统衰老负担的探索性指标。
- IL-23抑制治疗除控制皮肤炎症外,可能对表观遗传衰老有部分改善作用。
局限性
- 试点研究,样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While biologic therapies targeting interleukin-23 control cutaneous inflammation in psoriasis, their impact on epigenetic aging has not been previously demonstrated. OBJECTIVES: To evaluate the effects of tildrakizumab treatment in the epigenetic aging deviation of moderate-to severe psoriasis. METHODS: In an open-label 52-week clinical trial, 20 adults with psoriasis were treated with tildrakizumab-asmn 100 mg injections until week 28. Ten age-matched controls without psoriasis were enrolled. Genome-wide DNA methylation was profiled in peripheral blood leukocyte DNA (MethylationEPICv2.0, Illumina) to calculate epigenetic aging clocks predictive of all-cause-mortality, phenotypic age, chronological age, pace of aging, and telomere length. Epigenetic age deviation was calculated as the residuals against chronological age. RESULTS: Psoriasis patients had increased epigenetic age deviation in clocks predictive of mortality: PCGrimAge (P = .008), cytosine-phosphate-guanine (CpG) PTPCGrimAge3 (P = .019), CpGPTGrimAge3 (P = .019), GrimAge2 (P = .049). PCGrimAge was reversed by 0.3 years (week 28, P = .005) and 0.5 years (week 52, P = .04) after the use of tildrakizumab-asmn. The pace of aging was increased in psoriasis patients: DunedinPACE (P = .049). LIMITATIONS: Pilot study (small sample size). CONCLUSIONS: Psoriasis patients presented accelerated epigenetic aging in mortality-predictive clocks. Treatment with tildrakizumab-asmn (interleukin-23 inhibition) showed partial reversal of those clocks in 28 weeks. (Funded by Sun Pharmaceutical Industries, Inc; ClinicalTrials.gov number, NCT05110313).
引用
- Macit B, Benca-Bachman CE, Qureshi A, et al. The effects of tildrakizumab in the epigenetic aging deviation of psoriasis: A 52-week open-label study. J Am Acad Dermatol. 2026. PMID: 42617697. doi:10.1016/j.jaad.2026.08.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。